Form 4: REGENXBIO CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
REGENXBIO Inc.'s CEO, Curran Simpson, sold 20,811 shares of common stock for $12.62 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Curran Simpson, Chief Executive Officer and Director of REGENXBIO Inc. (RGNX), reported a sale of common stock.
- The transaction involved the disposition of 20,811 shares of common stock.
- The shares were sold at a weighted average price of $12.62 per share, with individual trades ranging from $12.50 to $12.84.
- This transaction was executed on October 9, 2025, pursuant to a Rule 10b5-1 trading plan.
- Following this transaction, Curran Simpson directly beneficially owns 216,162 shares of common stock.
Sentiment
Score: 5
Explanation: The sale of shares by the CEO was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned liquidity event or diversification strategy rather than a reaction to new material non-public information. This generally leads to a neutral interpretation by the market.
Positives
- NA
Negatives
- The Chief Executive Officer disposed of 20,811 shares of common stock, which reduces insider ownership.
Risks
- NA
Future Outlook
NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders may note the reduction in the CEO's direct ownership, though the pre-arranged nature of the 10b5-1 plan typically mitigates concerns about adverse implications for company performance.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 10/09/2025 | Date of earliest transaction (sale of common stock) |
| 10/10/2025 | Signature date of the reporting person's attorney-in-fact |
Recommendation
holdThe reported transaction is a sale of common stock by the CEO under a Rule 10b5-1 trading plan. Such plans are established in advance to allow insiders to sell shares without being accused of trading on material non-public information. This type of transaction is typically for personal financial planning, diversification, or liquidity purposes and does not inherently signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.
Keywords
REGENXBIO, RGNX, Curran Simpson, CEO, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.